Business, energy, technology, markets and global industry news from Business News Today

SkinJect

PharmaDeviceNews SkinJect
Representative image: A clinician applies a microneedle skin patch as Medicus Pharma $MDCX advances its SkinJect treatment into an FDA-cleared Phase 2b study for basal cell carcinomas in Gorlin syndrome.
Pharma & Biotech

FDA clears Medicus Pharma SkinJect registrational study in Gorlin syndrome

FDA clears Medicus Pharma’s Phase 2b SkinJect study in Gorlin syndrome with biopsy-confirmed endpoints and two-year follow-up.

Read More
Pharma & Biotech

What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers

Discover how SkinJect’s orphan drug bid could reshape Hedgehog-driven cancer treatment. Read what it means for clinicians, regulators, and investors.

Read More